Upstream pharmaceutical supply chains of 10 high-use pharmaceuticals in the Netherlands: a cohort study
Our study of the supply chains of high-use pharmaceutical substances indicates the need for a granular assessment of the interdependencies between MAHs, API and FPP manufacturers to identify upstream supply chain vulnerabilities.
Authors
- Kim Notenboom
- Hubert G. M. Leufkens (ORCID: https://orcid.org/0000-0002-7175-1499)
- Peter A. G. M. De Smet (ORCID: https://orcid.org/0000-0003-1762-6547)
- Aukje K. Mantel‐Teeuwisse (ORCID: https://orcid.org/0000-0002-8782-0698)
- Doerine J. Postma (ORCID: https://orcid.org/0000-0001-7129-1624)
Institutions
- Radboud University Nijmegen (NL)
- Utrecht University (NL)
- Royal Dutch Pharmacists Association (NL)
- Pharmo Institute (NL)
- Royal Dutch Society for the Promotion of Dentistry (NL)
- Medicines Evaluation Board (NL)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-099697
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 6.26